Dutasteride Microparticle Injection for 3-Month Sustained Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing dutasteride formulations, such as AVODART®, are inconvenient due to large excipient volume, requiring daily dosing and lacking sustained-release capabilities for treating prostatic hyperplasia, prostate cancer, and alopecia.
Innovation Solution
A sustained-release injectable composition containing dutasteride microparticles with uniform diameter (30-90 μm) and biodegradable polymers, releasing dutasteride for 3-6 months, maintaining effective plasma concentration, and minimizing foreign body sensation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If daily dosing is used to maintain therapeutic effect, then drug efficacy is maintained, but patient convenience deteriorates due to frequent administration
Solution Approach 1:
The drug is divided into multiple microparticles (30-90 μm diameter) containing dutasteride, which are then injected as a suspension. This segmentation allows the drug to be released gradually from each microparticle over time, extending the therapeutic effect from daily dosing to once-monthly or once-quarterly dosing while maintaining continuous therapeutic coverage.
Solution Approach 2:
The microparticles are pre-formulated with controlled release characteristics before injection. The biodegradable polymer matrix is designed to degrade at a controlled rate, releasing dutasteride over an extended period. This preliminary preparation eliminates the need for frequent dosing by establishing a sustained release mechanism in advance.
2Object-affected harmful factors
If microparticle size is reduced to improve injection comfort, then foreign body sensation decreases, but drug release control becomes more difficult
Solution Approach 1:
The microparticle diameter is optimized to the specific range of 30-90 μm, which balances two competing requirements: small enough to reduce foreign body sensation and improve injection comfort, yet large enough to maintain controlled drug release kinetics. This parameter optimization ensures both patient comfort and therapeutic efficacy.
Solution Approach 2:
The microparticles are constructed as composite materials with a biodegradable polymer matrix (such as PLGA) encapsulating dutasteride. This composite structure allows the polymer to provide structural integrity and controlled degradation for drug release, while the small particle size provides comfort. The biodegradable polymer gradually breaks down in the body, releasing the drug in a controlled manner despite the small particle dimensions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition provides continuous therapeutic effects for 3-6 months with reduced dosing frequency, controlled drug release, and minimized injection discomfort.
Implementation Method 1
the microparticles release the dutasteride in a sustained manner for 3 to 6 months after being injected in vivo
Implementation Method 2
the microparticles release the dutasteride in a sustained manner for 3 to 6 months after being injected in vivo
Data Source
AI summary
An embodiment relates to a sustained-release injectable composition containing dutasteride, which may exhibit a sustained dutasteride release effect for 3 months or more even when the dose of dutasteride is equal to or less than that of existing AVODART®, which is taken once a day, thereby exhibiting a long-acting drug effect by a single injection. In addition, the injectable composition may exhibit a therapeutic effect on benign prostatic hyperplasia, prostate cancer, and hair loss continuously for 3 months or more, may maintain an effective concentration of the drug at a constant level by controlling the release of the drug due to the constant average diameter of the microparticles contained in the sustained-release injectable composition, and may reduce foreign body sensation and pain when administered by injection to a patient.